Isthmus Partners LLC Trims Stock Position in Utah Medical Products, Inc. $UTMD

Isthmus Partners LLC lessened its position in shares of Utah Medical Products, Inc. (NASDAQ:UTMD) by 75.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 9,233 shares of the medical instruments supplier’s stock after selling 29,050 shares during the quarter. Isthmus Partners LLC owned about 0.29% of Utah Medical Products worth $517,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Comerica Bank raised its position in shares of Utah Medical Products by 435.6% during the 3rd quarter. Comerica Bank now owns 541 shares of the medical instruments supplier’s stock valued at $34,000 after buying an additional 440 shares during the period. BNP Paribas Financial Markets raised its position in shares of Utah Medical Products by 89.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,060 shares of the medical instruments supplier’s stock valued at $67,000 after buying an additional 501 shares during the period. CWM LLC raised its position in shares of Utah Medical Products by 60.4% during the 3rd quarter. CWM LLC now owns 1,330 shares of the medical instruments supplier’s stock valued at $84,000 after buying an additional 501 shares during the period. Cornerstone Planning Group LLC raised its position in Utah Medical Products by 3,272.5% in the third quarter. Cornerstone Planning Group LLC now owns 1,349 shares of the medical instruments supplier’s stock valued at $85,000 after purchasing an additional 1,309 shares during the period. Finally, State of Wyoming purchased a new stake in Utah Medical Products in the second quarter valued at approximately $132,000. Hedge funds and other institutional investors own 69.60% of the company’s stock.

Utah Medical Products Stock Down 0.6%

Shares of NASDAQ UTMD opened at $63.34 on Friday. The firm has a market cap of $201.42 million, a price-to-earnings ratio of 18.74 and a beta of 0.37. Utah Medical Products, Inc. has a 52-week low of $52.00 and a 52-week high of $71.81. The business’s 50 day moving average is $65.09 and its two-hundred day moving average is $61.40.

Utah Medical Products (NASDAQ:UTMD) last announced its earnings results on Thursday, April 23rd. The medical instruments supplier reported $0.82 earnings per share (EPS) for the quarter. The company had revenue of $8.72 million for the quarter. Utah Medical Products had a return on equity of 9.13% and a net margin of 28.90%.

Utah Medical Products Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 3rd. Shareholders of record on Wednesday, June 17th will be given a $0.31 dividend. The ex-dividend date of this dividend is Wednesday, June 17th. This represents a $1.24 dividend on an annualized basis and a yield of 2.0%. Utah Medical Products’s payout ratio is presently 36.69%.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised Utah Medical Products from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, February 25th. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat, the stock currently has an average rating of “Hold”.

Utah Medical Products Company Profile

Utah Medical Products, Inc (NASDAQ: UTMD), headquartered in Midvale, Utah, is a designer, manufacturer and marketer of single‐use medical devices focusing principally on respiratory therapy and patient monitoring applications. Since its founding in the late 1970s, the company has built a reputation for innovation in airway management and non‐invasive monitoring products used in acute and long‐term care settings.

The company’s core product portfolio includes tracheostomy tubes and related accessories, endotracheal tube holders, disposable catheters and sensors for measuring end‐tidal carbon dioxide (CO₂).